Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives

Seraina Faes, Nicolas Demartines and Olivier Dormond*

Department of Visceral Surgery, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies.

Keywords: mTOR, rapalogs, renal cell carcinoma, HIF-α, angiogenesis

INTRODUCTION

Renal cell carcinoma (RCC), which originates from the kidney epithelium, is the most frequent form of kidney cancer (Hsieh et al., 2017b; Nabi et al., 2018; Kotecha et al., 2019). RCC comprises several histological and molecular subtypes of which clear cell RCC is the most frequent (Moch et al., 2016). Curative surgery is possible in patients with localized RCC (Ljungberg et al., 2015). Unfortunately, many patients present in advanced, metastatic stages at diagnosis, and progression of a localized to an advanced stage is frequent despite surgery. Since advanced RCC is associated with high mortality, a strong need exists to develop appropriate systemic treatments. In this context, major progress has been achieved recently, and today, several therapeutic options exist, including immunotherapy and targeted therapies against vascular endothelial growth factor (VEGF) or mechanistic target of rapamycin (mTOR) signaling pathway (Hsieh et al., 2017b; Kotecha et al., 2019). Nevertheless, the efficacy of these therapies is limited, and disease progression is inevitable in most patients. Therefore, it is important to gain further knowledge regarding the biology of RCC in order to design successful therapies.

mTOR is a serine/threonine kinase that belongs to two distinct protein complexes, named mTORC1 and mTORC2. mTORC1 controls several processes involved in cell growth and proliferation including protein, lipid, and nucleotide synthesis (Saxton and Sabatini, 2017). Inhibition of mTORC1 by allosteric inhibitors generally termed rapalogs results in decreased cell proliferation and accordingly provides anticancer benefits (Waldner et al., 2016; Torri et al., 2020) in different types of cancer, including advanced RCC (Tian et al., 2019). The anticancer effect is however limited, and rapalogs are mostly prescribed as second- or third-line therapies. Although...
initially viewed as promising, mTORC1 inhibitors did not meet the expectations in RCC, and their roles need therefore to be readdressed. Here, the biologic rationale and limitations to use mTOR inhibitors in advanced RCC are reviewed. In addition, future roles that mTOR inhibitors might endorse in the treatment of advanced RCC are discussed.

ACTIVATION OF MECHANISTIC TARGET OF RAPAMYCIN IN RENAL CELL CARCINOMA

A major reason to target mTOR in RCC relies on the observation that, overall, mTOR contributes to cancer cell proliferation and survival, and mTOR signaling pathway is often activated in advanced RCC (Figure 1). In fact, genetic alterations of components of mTOR signaling pathway are frequently observed in RCC, underscoring the possible importance of mTOR in RCC development. For instance, 28% of clear cell RCC presents activating mutations of PI3K/AKT/mTOR signaling pathway that correlate with worse outcome (Cancer Genome Atlas Research, 2013). Similarly, 23% of chromophobe RCC displays genetic modifications of mTOR signaling pathway (Davis et al., 2014). Furthermore, expression of the activated forms of various components of the PI3K/AKT/mTOR signaling pathway was detected in a high percentage of RCC by immunohistochemistry (Lin et al., 2006; Pantuck et al., 2007; Abou Youssif et al., 2011).

mTOR inhibitors exert their antitumor effects in part by reducing cancer cell proliferation via blocking the G1-S cell cycle transition (Dufour et al., 2011). Decreased expression of cyclin D1 and upregulated levels of p27Kip1 have been observed in cancer cells as molecular basis for cell cycle blockage. Consistent with these findings, mTOR inhibitors induce G1 block in RCC cell lines in vitro and reduce cancer cell proliferation in RCC xenografts (Luan et al., 2003; Zhang et al., 2013; Zheng et al., 2015). Despite promising preclinical experiments, mTOR targeting agents have been less successful in expected in RCC patients. An initial phase III study tested the rapalog temsirolimus against interferon-α among patients with advanced RCC and poor prognosis (Hudes et al., 2007). Median overall survival was longer in the temsirolimus group compared with the interferon-α group (10.9 vs. 7.3 months). Similarly, everolimus was reported to increase progression-free survival compared with placebo in advanced RCC patients that had progressed on multi-targeted tyrosine kinase inhibitors (Motzer et al., 2008). Therefore, despite extensive activation of the PI3K/AKT/mTOR signaling pathway in advanced RCC, rapalogs display modest anticancer activity, suggesting that tumors do not depend on mTORC1 for growth and survival. This could be explained by the fact that upstream activators of mTORC1 such as PI3K or AKT activate several other downstream effectors that possess protumorigenic effects besides mTORC1 (Faes and Dormond, 2015). In addition, several resistance mechanisms might explain the limited efficacy of rapalogs including rapalog-resistant mutations of mTOR, activation of alternate proliferative pathways following mTORC1 inhibition, or tumor heterogeneity (Faes et al., 2017a). Finally, rapalogs only partially inhibit mTORC1, and therefore, a complete mTORC1 inhibition might be necessary to achieve better clinical outcome (Thoreen et al., 2009). In this context, kinase inhibitors of mTOR that display a complete inhibition of mTORC1 and that in contrast to rapalogs also inhibit mTORC2 have been developed (Benjamin et al., 2011). Preclinical studies have demonstrated that kinase inhibitor of mTOR are superior to rapalogs in RCC models (Cho et al., 2010; Ingels et al., 2014; Zheng et al., 2015). Unfortunately, such results were not confirmed in clinical settings. Two randomized phase 2 trials showed that the kinase inhibitor of mTOR AZD2014 (Powles et al., 2016b) and the dual PI3K/mTOR inhibitor GDC-0980 (Powles et al., 2016a) were inferior to everolimus in RCC patients who had progressed following exposure to VEGF pathway targeting therapies. Finally, a third-generation inhibitor named rapalink-1 and composed of rapamycin linked to the kinase inhibitor of mTOR MLN0128 provides improved antitumor activity in RCC models compared with temsirolimus (Kuroshima et al., 2020).

Nevertheless, a small minority of RCC patients respond to rapalogs, highlighting the need to identify biomarkers that could predict patients benefiting from rapalogs. Conceptually, cancers in which mTOR is a driving force with few heterogeneity represent the ideal candidate (Rodriguez-Moreno et al., 2017). In this context, the histologic subtypes is not helpful in selecting patients. It was indeed reported that temsirolimus was efficient.
in patients regardless of tumor histology (Dutcher et al., 2009). Similar results were observed in a retrospective study analyzing the effect of temsirolimus and everolimus in RCC with sarcomatoid or non-clear cell histologies (Voss et al., 2014a). Genetic analysis of mTOR pathway mutations has also provided mitigated results so far (Table 1). In fact, two out of five patients who showed exceptional response to rapalogs lacked mTOR signaling pathway activating mutations (Voss et al., 2014b). Similarly, in another cohort of RCC patients treated with rapalogs, 56% of responders had no genetic finding to explain their response (Kwiatkowski et al., 2016). Epigenetic mechanisms or direct effects of rapalogs on the tumor microenvironment might be at play. Nevertheless, mutations in tuberous sclerosis proteins TSC1 or TSC2, close upstream regulators of mTORC1, and mTOR are more common among rapalog responders (Kwiatkowski et al., 2016; Roldan-Romero et al., 2017). More promisingly, loss of PTEN expression, and not loss-of-function mutations, has recently been associated with everolimus therapeutic response (Voss et al., 2019; Roldan-Romero et al., 2020). Clearly, additional work is however required to identify reliable and robust combinations of biomarkers of response that can be used in clinic. Interestingly, a complete analysis of exceptional responders to rapalogs (mean progression-free survival of 28 months) revealed convergent mutations resulting in mTOR pathway activation (Voss et al., 2014b). It was therefore proposed that RCC development behaves rather like a braided river than a branching tree (Hsieh and Cheng, 2016; Hsieh et al., 2017a). This parallel convergent evolution of kidney cancer would thus offer significant therapeutic opportunities despite tumor heterogeneity.

Since rapalogs alone provide little benefits, several trials have explored mTOR inhibitors in combination therapies. In particular, combinations of rapalogs with anti-angiogenic drugs including, sorafenib, sunitinib, and bevacizumab have been tested (Ravaud et al., 2013). Most trials were however discontinued or required dose modification due to drug toxicity. In fact mTOR inhibitors are associated with substantial side effects such as mucositis, rash, myelosuppression, hyperglycemia, hypophosphatemia, hypercholesterolemia, and pneumonitis, limiting their application in cancer patients (Rodriguez-Pascual et al., 2010; Pallet and Legendre, 2013). Nevertheless, combining lenvatinib with everolimus resulted in an acceptable safety profile and has been approved for RCC patients who had received prior antiangiogenic treatments (Motzer et al., 2015).

### ANTI-ANGIOGENIC EFFECTS OF MECHANISTIC TARGET OF RAPAMYCIN INHIBITORS IN RENAL CELL CARCINOMA

RCCs are highly vascularized tumors, and the therapeutic benefits of anti-VEGF signaling therapies underline the role of angiogenesis in RCC development (Hsieh et al., 2017b). In this context, targeting mTOR represents a treatment strategy, as mTOR controls several processes implicated in tumor angiogenesis (Faes et al., 2017b). In fact, mTOR is an important signaling intermediary that regulates endothelial functions relevant to angiogenesis such as proliferation, survival, and migration (Akselband et al., 1991; Bruns et al., 2004; Dormond et al., 2007). Furthermore, mTOR modulates tumor angiogenesis

### TABLE 1 | RCC genetic analysis and response to rapalogs.

| Patients | Genetic alterations | Results | References |
|----------|---------------------|---------|------------|
| 79 selected RCC patients treated with rapalogs | Mutation or mTOR pathway mutation | Responders\(^a\) | Kwiatkowski et al., 2016 |
| 45 RCC patients treated with rapalogs (five harboring mTOR related mutations) | Mutation | Response | Roldan-Romero et al., 2017 |
| Exceptional responder | Mutation | Disease free after 8 years' temsirolimus treatment | Rodriguez-Moreno et al., 2017 |
| 184 everolimus treated RCC patients | IHC staining | PFS (months) | Voss et al., 2019 |
| 105 rapalogs treated RCC patients | IHC staining | Responders\(^d\) | Roldan-Romero et al., 2020 |

\(^a\) Responders: PR or SD with any tumor shrinkage for 6 months.

\(^b\) Non-responders: PD during the first 3 months of therapy.

\(^c\) Responders: PR or SD and at least 6 months PFS.

\(^d\) Non-responders: PD or SD of <6 months PFS.

PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; IHC, immunohistochemistry; RCC, renal cell carcinoma.
by regulating the production of pro-angiogenic factors in particular VEGF (Guba et al., 2002). Accordingly, mTOR inhibitors decrease tumor angiogenesis in a variety of preclinical models (Faes et al., 2017b). However, the contribution of the anti-angiogenic effects of rapalogs in RCC patients remains to be demonstrated. Of note, combining the anti-VEGF bevacizumab to temsirolimus did not provide better results than bevacizumab with interferon-α, suggesting that bevacizumab and temsirolimus share inhibition of angiogenesis as a common anticancer effect (Rini et al., 2014). Nevertheless, the limited efficacy of rapalogs in advanced RCC challenges the anti-angiogenic efficacy of mTOR inhibitors. In fact, mTOR inhibitors had no impact on microvesSEL density of RCC xenografts, suggesting that in certain circumstances, tumor blood vessels are not sensitive to mTOR inhibitors, or the anti-angiogenic effects might only be transient (Cho et al., 2010; Ellis et al., 2012).

REGULATION OF HYPOXIA-INDUCIBLE FACTORS BY MECHANISTIC TARGET OF RAPAMYCIN

Clear cell RCC frequently harbors loss-of-function mutations of the tumor suppressor gene Von Hippel–Lindau (VHL). Consequently, hypoxia-inducible factors (HIF-1α and HIF-2α) accumulate, leading to a constant hypoxic tumor response that promotes tumor growth and angiogenesis despite the presence of oxygen (Patel et al., 2006; Shen and Kaelin, 2013). Therefore, targeting HIFs might influence RCC progression (Schodel et al., 2016). Interestingly, in contrast to initial thoughts, emerging evidence has now demonstrated a divergent role for HIF-α factors in RCC biology where HIF-1α reduces and HIF-2α promotes RCC growth (Kondo et al., 2002, 2003; Shen et al., 2011; Gudas et al., 2014; Hoeflflin et al., 2020).

Several reports have evidenced that mTOR decreases expression of HIF-α factors and therefore might influence RCC growth (Faes et al., 2017b). Consistent with this hypothesis, it was demonstrated that VHL mutation determines RCC sensitivity to temsirolimus in a mouse model of RCC (Thomas et al., 2006). Rapalogs decrease HIF-1α expression via different mechanisms including HIF-1α mRNA transcription, mRNA translation, protein stabilization, and transcriptional activity (Faes et al., 2017b). In contrast, HIF-2α expression depends on mTORC2 activity and is accordingly not affected by rapalogs (Toschi et al., 2008). In the context of RCC, opposing results have been reported regarding the effect of mTOR inhibitors on HIF-α factor expression. It was shown that temsirolimus reduces both HIF-1α and HIF-2α expression in RCC in vitro (Thomas et al., 2006). In contrast, whereas the dual PI3K/mTOR inhibitor NVP-BeZ235 decreased HIF-2α expression in 786-0, A498, Caki-1, and Caki-2 RCC cell lines, rapamycin had no significant effects (Cho et al., 2010). Taken together, these studies highlight the complex interrelationship between mTOR and HIF-α factors and suggest that preferential inhibition of HIF-1α expression over HIF-2α by rapalogs might provide detrimental protumorigenic signals. Nevertheless, a complete understanding of the role of HIF-α factors in RCC and the consequences of mTOR inhibition on their activities is necessary.

FUTURE DIRECTION: COMBINING MECHANISTIC TARGET OF RAPAMYCIN INHIBITORS WITH IMMUNOTHERAPIES

Following major therapeutic success by immunotherapy in melanoma, lot of efforts are deployed to design immunotherapy-based protocols in RCC. Interleukin-2 and interferon-α were initially used in patients with advanced RCC, suggesting that RCC might be particularly sensitive to immunotherapies. Accordingly, numerous clinical trials are currently exploring the effects of immunotherapy alone or in combination with various targeted therapies (Garje et al., 2020). Since rapalogs are mainly used to prevent rejection of transplanted organs, their use with immunotherapies seems aberrant at first look. However, emerging studies have demonstrated that mTOR inhibitors display immunostimulatory effects. Rapamycin increases memory CD8+ T cell differentiation following viral infection (Araki et al., 2009). Rapamycin treatment also induces stem-cell like memory T cells during activation of human naïve T cells (Scholz et al., 2016). In cancer, preclinical studies have shown that rapalogs enhance the tumor response to different types of immunotherapies including vaccines, adoptive T cell therapy, and checkpoint inhibitors (Thomas et al., 2011; Wang et al., 2011; Amiel et al., 2012; Li et al., 2012; Diken et al., 2013; Mineharu et al., 2014; Moore et al., 2016). Therefore, additional studies are needed to fully characterize the conditions in which mTOR inhibition results in immune stimulation or inhibition. Interestingly, the immune modulatory properties of rapalogs were assessed in RCC patients, and results confirmed that mTOR inhibitors provide opposing effects on the antitumor immune response (Beziaud et al., 2016; Huijts et al., 2017). In most patients, the rapalog everolimus promoted expansion of FoxP3+ regulatory T cells (Tregs) and increased spontaneous tumor-specific TH1 response. Importantly, in a subset of patients, everolimus decreased Treg levels while increasing TH1 response, which was associated with a longer progression-free survival. This suggests that the antitumor effects of rapalogs occur in part via modulation of the antitumor immune response and provide an additional rationale to combine mTOR inhibitors with immunotherapies.

The endothelial barrier is an important obstacle to recognize when considering combining anticancer agents with immunotherapies (Schmittnaegel and De Palma, 2017; Uldry et al., 2017). In fact, tumor blood perfusion is frequently reduced due to abnormal blood vessels, resulting in hypoxia and decreased delivery of anticancer agents and immune cells to tumors (Martin et al., 2019). Accordingly, tumor blood vessel normalization with anti-angiogenic drugs improves cancer immunotherapy by in part augmenting T cell extravasation (Allen et al., 2017; Schmittnaegel et al., 2017; Mpekris et al., 2020). Preclinical studies demonstrated contrasting results regarding the effects of mTOR inhibitors on tumor blood vessel normalization. On the one hand, reduction of vessel permeability...
and increased tumor perfusion by mTOR inhibitors were observed in different cancer models (Schnell et al., 2008; Zhang et al., 2011; Myers et al., 2012). On the other hand, absence of effects was also noted (Lane et al., 2009; Ellis et al., 2012). Therefore, applying mTOR inhibitors in conditions where they induce vessel normalization might be particularly beneficial with immunotherapies. Tumor blood vessels also actively participate to the recruitment of leukocytes into tumors by expressing adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1). In addition, they modulate T cell activity by expressing MHC class I and class II as well as co-stimulatory and co-inhibitory molecules (Choi et al., 2004). Of note, it was reported that mTOR inhibitors upregulate PD-L1 and PD-L2 and reduce VCAM-1 expression on endothelial cells (Wang et al., 2013, 2014). Consequently, rapamycin pretreatment of human arterial allografts decreased infiltration of artery intima by effector T cells. Although these findings need to be investigated in tumor models, they suggest that mTOR inhibitors might reinforce the tumor endothelial barrier and therefore counteract their benefits in the context of immunotherapy.

CONCLUSIONS

Despite clear implications of mTOR signaling pathway in RCC development and progression, inhibition of mTOR through rapalogs did not provide major and long-lasting anticancer benefits in patients. Whereas, mTOR is frequently activated in RCC and participates in tumor growth, RCC harbors major genetic heterogeneity, implying that many driving forces, not limited to mTOR, participate in tumor growth. Combination therapies might therefore provide additional antitumor effects, albeit increased toxicity. Although several preclinical studies have demonstrated that mTOR inhibitors decrease tumor angiogenesis, this specific mechanism in the context of RCC has not been thoroughly investigated. More importantly, some investigations in RCC mouse models did not find any inhibitory effect of rapalogs on the tumor vasculature. Finally, in a subset of RCC that presents VHL mutation, the preferential inhibition of HIF-1α over HIF-2α by rapalogs might decrease the tumor-suppressing effects of HIF-1α, counteracting the anticancer efficacy of rapalogs. Given the success of immunotherapies, future investigations addressing the role of mTOR inhibitors in RCC will certainly focus on their immunostimulatory effects. Accordingly, dissecting the conditions where mTOR inhibitors exert immunostimulatory instead of immunosuppressing activities will be key. Interestingly, a study demonstrated that some RCC patients preferentially presented increased antitumor response under rapalog treatment, highlighting their therapeutic potential in combination with immunotherapy.

AUTHOR CONTRIBUTIONS

SF and OD designed the manuscript. SF drafted the manuscript. OD and ND revised the manuscript. All authors have approved the final version of the manuscript.

FUNDING

This work was supported by grants to SF (bourse pro-femmes from the University of Lausanne) and to OD (KFS-4128-02-2017 from the Swiss Cancer League).

REFERENCES

Abou Youssif, T., Fahmy, M. A., Koumakpayi, I. H., Ayala, F., Al Marzooqi, S., Chen, G., et al. (2011). The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117, 290–300. doi: 10.1002/cncr.25402

Akselband, Y., Harding, M. W., and Nelson, P. A. (1991). Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc. 23, 2833–2836.

Allen, E., Jabouille, A., Rivera, L. B., Lodewijicks, I., Missiaen, R., Steri, V., et al. (2017). Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9:eaa99679. doi: 10.1126/scitranslmed.aak9679

Amiel, E., Everts, B., Freitas, T. C., King, I. L., Curtis, J. D., Pearce, E. L., et al. (2012). Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J. Immunol. 189, 2151–2158. doi: 10.4049/jimmunol.1103741

Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., et al. (2009). mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108–112. doi: 10.1038/nature08155

Benjamin, D., Colombi, M., Moroni, C., and Hall, M. N. (2011). Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10, 868–880. doi: 10.1038/nrd3301

Betzold, U., Mansi, L., Ravel, P., Marie-Joseph, E. L., Laheurte, C., Rangan, L., et al. (2016). Rapalogs efficacy relies on the modulation of antitumor T-cell immunity. Cancer Res. 76, 4100–4112. doi: 10.1158/0008-5472.CAN-15-2452

Bruns, C. J., Koehl, G. E., Guba, M., Yezhelyev, M., Steinbauer, M., Seeliger, H., et al. (2004). Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin. Cancer Res. 10, 2109–2119. doi: 10.1158/1078-0432.CCR-03-0502

Cancer Genome Atlas Research. (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49. doi: 10.1038/nature12222

Cho, D. C., Cohen, M. B., Panka, D. J., Collins, M., Ghebremichael, M., Atkins, M. B., et al. (2010). The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 16, 3628–3638. doi: 10.1158/1078-0432.CCR-09-3022

Choi, J., Enis, D. R., Koh, K. P., Shiao, S. L., and Pober, J. S. (2004). T lymphocyte-endothelial cell interactions. Annu. Rev. Immunol. 22, 683–709. doi: 10.1146/annurev.immunol.22.012703.104639

Davis, C. F., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., et al. (2014). The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330. doi: 10.1016/j.ccr.2014.07.014

Diken, M., Kreiter, S., Vascotto, F., Selmi, A., Attig, S., Diekmann, J., et al. (2013). mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol Res. 1, 386–392. doi: 10.1158/2326-6066.CIR-13-0046

Dormond, O., Madsen, J. C., and Briscoe, D. M. (2007). The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem. 282, 23679–23686. doi: 10.1074/jbc.M700563200

Dufour, M., Dormond-Meuly, A., Demartines, N., and Dormond, O. (2011). Targeting the Mammalian Target of Rapamycin (mTOR) in cancer therapy:
lessons from past and future perspectives. Cancers (Basel) 3, 2478–2500. doi: 10.3390/cancers3022478

Dutcher, J. P., de Souza, P., McDermott, D., Figlin, R. A., Berkenblit, A., Thiele, A., et al. (2009). Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26, 202–208. doi: 10.1007/s12032-009-9177-0

Ellis, L., Shah, P., Hammers, H., Leht, K., Sotomayor, P., Azadabafar, G., et al. (2012). Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol. Cancer Ther. 11, 383–392. doi: 10.1158/1535-7163.MCT-11-0748

Faes, S., Demartines, N., and Dombord, O. (2017a). Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratumoral heterogeneity of kinase activity. Oxid. Med. Cell. Longev. 2017:1267087. doi: 10.1155/2017/1276078

Faes, S., and Dombord, O. (2015). PI3K and AKT: unfaithful partners in cancer. Int. J. Mol. Sci. 16, 21138–21152. doi: 10.3390/ijms160921138

Faes, S., Santoro, T., Demartines, N., and Dormond, O. (2017b). Evolving mTOR Inhibitors in RCC tumor heterogeneity and precision medicine. Clin. Cancer Res. 15, 3080–3087. doi: 10.1158/1078-0432.CCR-15-0027

Lin, F., Rao, R., Vazana, J., Goedegebuure, P., Odunsii, K., Gillanders, W., et al. (2012). Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+)-T cell responses for tumor immunity. J. Immunol. 188, 3080–3087. doi: 10.4049/jimmunol.1103365

Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., et al. (2015). EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 93–924. doi: 10.1016/j.euro.2015.01.005

Luan, F. L., Ding, R., Sharma, V. K., Chon, W. J., Lagman, M., and Suthanthiran, M. (2003). Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 63, 917–926. doi: 10.1111/1523-1755.2003.00805.x

Martin, J. D., Seano, G., and Jain, R. K. (2019). Normalization of tumor vessels: progress, opportunities, and challenges. Annu. Rev. Pathol. 8, 505–534. doi: 10.1146/annurev-physiol-020518-114700

Mourad, Y., Kamran, N., Lowenstein, P. R., and Castro, M. G. (2014). Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antigenic cytotoxic and memory T-cell functions. Mol. Cancer Ther. 13, 3024–3036. doi: 10.1158/1535-7163.MCT-14-0400

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., and Ulbright, T. M. (2016). The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur. Urol. 70, 93–105. doi: 10.1016/j.euro.2016.02.029

Moore, E. C., Cash, H. A., Caruso, A. M., Uppaluri, R., Hodge, J. W., Van Waes, C., et al. (2016). Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol. Immunother. 65, 611–620. doi: 10.1186/s10029-016-0606-9

Motzer, R. J., Escudier, B., Oudard, S., Hutzon, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456. doi: 10.1016/S0140-6736(08)6039-9

Motzer, R. J., Hutzon, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., et al. (2015). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482. doi: 10.1016/S1470-2045(15)00290-9

Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., et al. (2015). Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol. Immunother. 64, 98–106. doi: 10.1007/s00262-014-1753-7

Nab, S., Kessler, E. R., Bernard, B., Flag, T. W., and Lam, E. T. (2018). Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 7:307. doi: 10.12688/f1000research.13179.1

Pallet, N., and Legendre, C. (2013). Adverse events associated with mTOR inhibitors. Expert. Opin. Drug Saf. 12, 177–186. doi: 10.1517/14740338.2013.752814

Pantuck, A. J., Sehlgon, D. B., Klattie, T., Yu, H., Leppert, J. T., Moore, L., et al. (2007). Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109, 2257–2267. doi: 10.1002/cncr.22677

Patel, P. H., Chadalavada, R. S., Chaganti, R. S., and Motzer, R. J. (2006). Targeting of von-Hippel-Lindau pathway in renal cell carcinoma. Clin. Cancer Res. 12, 7215–7220. doi: 10.1158/1078-0432.CCR-06-2254
